Download
1-s2.0-S1201971221001247-main.pdf 349,03KB
WeightNameValue
1000 Titel
  • Prioritizing second-generation SARS-CoV-2 vaccines through low-dosage challenge studies
1000 Autor/in
  1. Steuwer, Bastian |
  2. Jamrozik, Euzebiusz |
  3. Eyal, Nir |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-02-12
1000 Erschienen in
1000 Quellenangabe
  • 105:307-311
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1016/j.ijid.2021.02.038 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7881292 |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • The design of human challenge studies balances scientific validity, efficiency and study safety. This Perspective explores some advantages and disadvantages of ‘low-dosage’ challenge studies, in the setting of testing second-generation vaccines against COVID-19. Compared with a conventional vaccine challenge, a low-dosage vaccine challenge would be more likely to start, and start earlier. A low-dosage challenge would also be less likely to rule out a vaccine candidate that would have potentially been effective, particularly in certain target uses. A key ethical advantage of a low-dosage challenge over a conventional challenge is that both it and its dose escalation process are safer for each participant. Low-dosage studies would require larger numbers of participants than conventional challenges, but this and other potential disadvantages are less serious than they may initially appear. Overall, low-dosage challenges should be considered for certain roles such as prioritizing between second-generation vaccines against COVID-19.
1000 Sacherschließung
gnd 1206347392 COVID-19
lokal Ethics
lokal Research design
lokal Vaccines
lokal Human challenge studies
lokal Coronavirus
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/U3RldXdlciwgQmFzdGlhbg==|https://frl.publisso.de/adhoc/uri/SmFtcm96aWssIEV1emViaXVzeg==|https://frl.publisso.de/adhoc/uri/RXlhbCwgTmly
1000 Label
1000 Förderer
  1. National Science Foundation |
  2. Open Philanthropy Project |
  3. National Institute of Allergy and Infectious Diseases |
  4. Wellcome Trust |
1000 Fördernummer
  1. 2039320
  2. -
  3. AI114617-01A1
  4. 203132/Z/16/Z; 216355/Z/19/Z
1000 Förderprogramm
  1. -
  2. -
  3. -
  4. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer National Science Foundation |
    1000 Förderprogramm -
    1000 Fördernummer 2039320
  2. 1000 joinedFunding-child
    1000 Förderer Open Philanthropy Project |
    1000 Förderprogramm -
    1000 Fördernummer -
  3. 1000 joinedFunding-child
    1000 Förderer National Institute of Allergy and Infectious Diseases |
    1000 Förderprogramm -
    1000 Fördernummer AI114617-01A1
  4. 1000 joinedFunding-child
    1000 Förderer Wellcome Trust |
    1000 Förderprogramm -
    1000 Fördernummer 203132/Z/16/Z; 216355/Z/19/Z
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6427609.rdf
1000 Erstellt am 2021-05-20T09:36:19.810+0200
1000 Erstellt von 284
1000 beschreibt frl:6427609
1000 Bearbeitet von 25
1000 Zuletzt bearbeitet Wed Sep 29 08:12:38 CEST 2021
1000 Objekt bearb. Wed Sep 29 08:12:26 CEST 2021
1000 Vgl. frl:6427609
1000 Oai Id
  1. oai:frl.publisso.de:frl:6427609 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source